David B Solit

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5561227/publications.pdf

Version: 2024-02-01

335 papers	57,974 citations	902 116 h-index	1185 228 g-index
353 all docs	353 docs citations	353 times ranked	57988 citing authors

#	Article	IF	Citations
1	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nature Genetics, 2019, 51, 202-206.	9.4	2,702
2	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	15.2	2,473
3	mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt. Cancer Research, 2006, 66, 1500-1508.	0.4	2,329
4	Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature, 2012, 486, 532-536.	13.7	1,605
5	Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature, 2012, 487, 500-504.	13.7	1,561
6	RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature, 2011, 480, 387-390.	13.7	1,298
7	OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017, 2017, 1-16.	1.5	1,266
8	BRAF mutation predicts sensitivity to MEK inhibition. Nature, 2006, 439, 358-362.	13.7	1,264
9	AACR Project GENIE: Powering Precision Medicine through an International Consortium. Cancer Discovery, 2017, 7, 818-831.	7.7	1,235
10	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. New England Journal of Medicine, 2016, 375, 443-453.	13.9	1,205
11	Molecular Determinants of Response to Antiâ€“Programmed Cell Death (PD)-1 and Antiâ€“Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Nonâ€“Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. Journal of Clinical Oncology, 2018, 36, 633-641.	0.8	1,109
12	Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science, 2018, 359, 582-587.	6.0	834
13	Genome Sequencing Identifies a Basis for Everolimus Sensitivity. Science, 2012, 338, 221-221.	6.0	681
14	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. Nature Biotechnology, 2016, 34, 155-163.	9.4	634
15	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	7.7	633
16	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell, 2018, 33, 125-136.e3.	7.7	589
17	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. Cell Stem Cell, 2017, 21, 374-382.e4.	5.2	578
18	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature, 2018, 554, 189-194.	13.7	572

#	Article	IF	Citations
19	Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell, 2018, 173, 515-528.e17.	13.5	540
20	Akt Forms an Intracellular Complex with Heat Shock Protein 90 (Hsp90) and Cdc37 and Is Destabilized by Inhibitors of Hsp90 Function. Journal of Biological Chemistry, 2002, 277, 39858-39866.	1.6	539
21	^{V600E} BRAF is associated with disabled feedback inhibition of RAFâ€“MEK signaling and elevated transcriptional output of the pathway. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4519-4524.	3.3	535
22	Tumor adaptation and resistance to RAF inhibitors. Nature Medicine, 2013, 19, 1401-1409.	15.2	512
23	Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma. Cancer Discovery, 2014, 4, 1140-1153.	7.7	506
24	Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies. Cancer Discovery, 2017, 7, 596-609.	7.7	490
25	Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles forBRAF, PIK3CA, andAKT1. Cancer Research, 2009, 69, 4885-4893.	0.4	488
26	Convergent loss of PTEN leads to clinical resistance to a PI(3)KÎ± inhibitor. Nature, 2015, 518, 240-244.	13.7	486
27	High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants. Nature Medicine, 2019, 25, 1928-1937.	15.2	485
28	Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncology, 2019, 5, 471.	3.4	426
29	The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14903-14908.	3.3	417
30	Genome doubling shapes the evolution and prognosis of advanced cancers. Nature Genetics, 2018, 50, 1189-1195.	9.4	411
31	Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. Journal of Clinical Oncology, 2018, 36, 1685-1694.	0.8	399
32	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. Journal of Clinical Oncology, 2019, 37, 286-295.	0.8	397
33	HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab. Clinical Cancer Research, 2011, 17, 5132-5139.	3.2	396
34	Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature, 2017, 548, 234-238.	13.7	394
35	BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition. Cancer Cell, 2015, 28, 370-383.	7.7	392
36	Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next-Generation Sequencing for Matching Patients to Targeted and Immune Therapies. Clinical Cancer Research, 2019, 25, 2116-2126.	3.2	390

#	Article	IF	Citations
37	Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. Journal of Clinical Oncology, 2018, 36, 2532-2537.	0.8	381
38	The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell, 2005, 8, 287-297.	7.7	372
39	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	7.7	372
40	Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nature Genetics, 2020, 52, 1219-1226.	9.4	367
41	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. JAMA - Journal of the American Medical Association, 2017, 318, 825.	3.8	366
42	4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors. Cancer Cell, 2010, 18, 39-51.	7.7	360
43	17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts. Clinical Cancer Research, 2002, 8, 986-93.	3.2	357
44	Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. Clinical Cancer Research, 2018, 24, 4154-4161.	3.2	348
45	PIK3CA Mutation Associates with Improved Outcome in Breast Cancer. Clinical Cancer Research, 2009, 15, 5049-5059.	3.2	338
46	Somatic mutations of the Parkinson's diseaseâ€“associated gene PARK2 in glioblastoma and other human malignancies. Nature Genetics, 2010, 42, 77-82.	9.4	336
47	Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2â€“Overexpressing Breast Cancer: A Phase I Dose-Escalation Study. Journal of Clinical Oncology, 2007, 25, 5410-5417.	0.8	333
48	Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation. Nature Genetics, 2013, 45, 253-261.	9.4	324
49	Effects of Co-occurring Genomic Alterations on Outcomes in Patients withKRAS-Mutant Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 334-340.	3.2	323
50	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biology, 2014, 15, 454.	3.8	296
51	Tumour lineage shapes BRCA-mediated phenotypes. Nature, 2019, 571, 576-579.	13.7	295
52	Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nature Biotechnology, 2004, 22, 701-706.	9.4	288
53	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. JCO Precision Oncology, 2017, 2017, 1-16.	1.5	286
54	Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer. Journal of Clinical Oncology, 2013, 31, 3133-3140.	0.8	282

#	Article	IF	Citations
55	PTEN Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. JCO Precision Oncology, 2017, 1, 1-15.	1.5	275
56	Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discovery, 2018, 8, 174-183.	7.7	275
57	Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer. Cancer Discovery, 2018, 8, 49-58.	7.7	275
58	Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nature Genetics, 2011, 43, 964-968.	9.4	270
59	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. JAMA Oncology, 2016, 2, 104.	3.4	270
60	A Phase Ib Study of Alpelisib (BYL719), a PI3KÎ±-Specific Inhibitor, with Letrozole in ER+/HER2â^' Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 26-34.	3.2	268
61	Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence. Cancer Research, 2014, 74, 2340-2350.	0.4	266
62	Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets. European Urology, 2017, 72, 952-959.	0.9	263
63	Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas. Journal of Clinical Oncology, 2012, 30, 2956-2962.	0.8	254
64	Development and application of Hsp90 inhibitors. Drug Discovery Today, 2008, 13, 38-43.	3.2	253
65	Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene, 2002, 21, 1159-1166.	2.6	251
66	The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 9435-9440.	3.3	246
67	Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer. Cancer Research, 2010, 70, 5901-5911.	0.4	245
68	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial. Lancet Oncology, The, 2020, 21, 821-831.	5.1	243
69	AKT Inhibition in Solid Tumors With AKT1 Mutations. Journal of Clinical Oncology, 2017, 35, 2251-2259.	0.8	240
70	Genetic Predictors of MEK Dependence in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2008, 68, 9375-9383.	0.4	235
71	Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Research, 2003, 63, 2139-44.	0.4	227
72	DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma. Clinical Cancer Research, 2017, 23, 3610-3618.	3.2	225

#	Article	IF	Citations
73	Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell, 2022, 185, 563-575.e11.	13.5	223
74	Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244). Cancer Research, 2010, 70, 2264-2273.	0.4	222
75	Resistance to BRAF Inhibition in Melanomas. New England Journal of Medicine, 2011, 364, 772-774.	13.9	222
76	Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment. New England Journal of Medicine, 2012, 367, 2316-2321.	13.9	222
77	Hsp90: the vulnerable chaperone. Drug Discovery Today, 2004, 9, 881-888.	3.2	219
78	Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clinical Cancer Research, 2003, 9, 4340-6.	3.2	214
79	Novel MEK1 Mutation Identified by Mutational Analysis of Epidermal Growth Factor Receptor Signaling Pathway Genes in Lung Adenocarcinoma. Cancer Research, 2008, 68, 5524-5528.	0.4	206
80	Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels. Journal of Clinical Oncology, 2016, 34, 2141-2147.	0.8	204
81	Genomic Characterization of Upper Tract Urothelial Carcinoma. European Urology, 2015, 68, 970-977.	0.9	202
82	Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance. Clinical Cancer Research, 2018, 24, 3108-3118.	3.2	200
83	Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer. Clinical Cancer Research, 2007, 13, 1775-1782.	3.2	198
84	BRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors. Cancer Discovery, 2012, 2, 791-797.	7.7	194
85	Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma. Clinical Cancer Research, 2008, 14, 8302-8307.	3.2	193
86	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. JAMA Oncology, 2017, 3, 244.	3.4	191
87	SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase Dependent Cancers. Clinical Cancer Research, 2008, 14, 240-248.	3.2	175
88	Inhibition of Hsp90 Down-regulates Mutant Epidermal Growth Factor Receptor (EGFR) Expression and Sensitizes EGFR Mutant Tumors to Paclitaxel. Cancer Research, 2008, 68, 589-596.	0.4	172
89	Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Annals of Oncology, 2017, 28, 512-518.	0.6	171
90	BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer, 2014, 120, 2316-2324.	2.0	170

#	Article	IF	Citations
91	3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional targets. Genome Medicine, 2017, 9, 4.	3.6	170
92	BRAF Mutation is associated with early stage disease and improved outcome in patients with lowâ€grade serous ovarian cancer. Cancer, 2013, 119, 548-554.	2.0	169
93	Hsp90: A Novel Target for Cancer Therapy. Current Topics in Medicinal Chemistry, 2006, 6, 1205-1214.	1.0	164
94	Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma. Clinical Cancer Research, 2019, 25, 967-976.	3.2	164
95	Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Clinical Cancer Research, 2017, 23, 6094-6100.	3.2	161
96	The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) â‰¥10: a decision centered on empowering patients and their physicians. Annals of Oncology, 2020, 31, 1115-1118.	0.6	161
97	Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response. Clinical Cancer Research, 2010, 16, 3329-3334.	3.2	160
98	Targeting Wide-Range Oncogenic Transformation via PU24FCl, a Specific Inhibitor of Tumor Hsp90. Chemistry and Biology, 2004, 11, 787-797.	6.2	159
99	New Efficient Synthesis of Resorcinylic Macrolides via Ynolides:â€‰ Establishment of Cycloproparadicicol as Synthetically Feasible Preclinical Anticancer Agent Based on Hsp90 as the Target. Journal of the American Chemical Society, 2004, 126, 7881-7889.	6.6	159
100	Phase <scp>II</scp> study of everolimus in metastatic urothelial cancer. BJU International, 2013, 112, 462-470.	1.3	153
101	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. Clinical Cancer Research, 2016, 22, 4623-4633.	3.2	153
102	HER2-Mediated Internalization of Cytotoxic Agents inERBB2Amplified or Mutant Lung Cancers. Cancer Discovery, 2020, 10, 674-687.	7.7	149
103	Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. Journal of Clinical Oncology, 2016, 34, 4000-4007.	0.8	147
104	PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling. Cancer Research, 2010, 70, 6804-6814.	0.4	146
105	RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer, 2015, 121, 1195-1203.	2.0	146
106	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nature Genetics, 2016, 48, 356-358.	9.4	143
107	Hsp90 as a therapeutic target in prostate cancer. Seminars in Oncology, 2003, 30, 709-716.	0.8	140
108	Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors. JAMA Oncology, 2018, 4, 1589.	3.4	139

#	Article	IF	Citations
109	The association between tumor mutational burden and prognosis is dependent on treatment context. Nature Genetics, 2021, 53, 11-15.	9.4	139
110	Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma. Clinical Cancer Research, 2013, 19, 2257-2264.	3.2	136
111	Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials. Drug Discovery Today, 2015, 20, 1422-1428.	3.2	136
112	Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET. Journal of Nuclear Medicine, 2006, 47, 793-6.	2.8	136
113	Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. Journal of Clinical Investigation, 2019, 129, 4276-4289.	3.9	134
114	Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2010, 28, 4240-4246.	0.8	129
115	Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel. Clinical Cancer Research, 2005, 11, 1983-1989.	3.2	128
116	Perturbation Biology: Inferring Signaling Networks in Cellular Systems. PLoS Computational Biology, 2013, 9, e1003290.	1.5	128
117	MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with Smoking. Clinical Cancer Research, 2015, 21, 1935-1943.	3.2	124
118	Genomic Predictors of Survival in Patients with High-grade Urothelial Carcinoma of the Bladder. European Urology, 2015, 67, 198-201.	0.9	122
119	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature Medicine, 2019, 25, 1839-1842.	15.2	122
120	The current state of preclinical prostate cancer animal models. Prostate, 2008, 68, 629-639.	1.2	121
121	HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Molecular Cancer Therapeutics, 2008, 7, 3499-3508.	1.9	121
122	Pilot Trial of Unlabeled and Indium-111â€“Labeled Antiâ€“Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer. Clinical Cancer Research, 2005, 11, 7454-7461.	3.2	120
123	EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer. Cancer Discovery, 2019, 9, 199-209.	7.7	115
124	Synthetic Lethality in ATM-Deficient RAD50-Mutant Tumors Underlies Outlier Response to Cancer Therapy. Cancer Discovery, 2014, 4, 1014-1021.	7.7	114
125	Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium. Annals of Oncology, 2019, 30, 597-603.	0.6	114
126	BRAFV600E Mutation Is Associated with Preferential Sensitivity to Mitogen-Activated Protein Kinase Kinase Inhibition in Thyroid Cancer Cell Lines. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2194-2201.	1.8	112

#	Article	IF	Citations
127	Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate Cancer. Clinical Cancer Research, 2020, 26, 3230-3238.	3.2	112
128	Resistance to MEK Inhibitors: Should We Co-Target Upstream?. Science Signaling, 2011, 4, pe16.	1.6	110
129	Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer. Journal of Clinical Oncology, 2018, 36, 1949-1956.	0.8	110
130	Genomic Complexity and AKT Dependence in Serous Ovarian Cancer. Cancer Discovery, 2012, 2, 56-67.	7.7	109
131	Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nature Biotechnology, 2008, 26, 91-100.	9.4	108
132	Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors. PLoS ONE, 2007, 2, e810.	1.1	107
133	Genomic Correlates of Disease Progression and Treatment Response in Prospectively Characterized Gliomas. Clinical Cancer Research, 2019, 25, 5537-5547.	3.2	107
134	Development of Purine-Scaffold Small Molecule Inhibitors of Hsp90. Current Cancer Drug Targets, 2003, 3, 371-376.	0.8	106
135	ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2019, 25, 977-988.	3.2	104
136	Genomic Differences Between â€œPrimaryâ€•and â€œSecondaryâ€•Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. European Urology, 2019, 75, 231-239.	0.9	104
137	Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and <scp>TERT</scp> promoter hotspot mutations and TERT gene amplification as likely drivers of progression. Journal of Pathology, 2016, 238, 508-518.	2.1	102
138	Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clinical Cancer Research, 2018, 24, 5939-5947.	3.2	100
139	Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties. Cancer Discovery, 2018, 8, 648-661.	7.7	97
140	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nature Cancer, 2020, 1, 382-393.	5.7	96
141	Perturbation biology nominates upstreamâ€“downstream drug combinations in RAF inhibitor resistant melanoma cells. ELife, 2015, 4, .	2.8	95
142	Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. JCO Precision Oncology, 2020, 4, 355-366.	1.5	93
143	Phase I Study of Samarium-153 Lexidronam With Docetaxel in Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology, 2009, 27, 2436-2442.	0.8	92
144	Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E748-57.	3.3	90

#	Article	IF	Citations
145	Presence of Somatic Mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in Cisplatin-Resistant Germ Cell Tumors. Clinical Cancer Research, 2014, 20, 3712-3720.	3.2	88
146	Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. Journal of Clinical Oncology, 2015, 33, 4099-4105.	0.8	88
147	An Acquired HER2â€ˆT798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutantâ€“Driven Breast Cancer. Cancer Discovery, 2017, 7, 575-585.	7.7	85
148	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clinical Cancer Research, 2018, 24, 1965-1973.	3.2	85
149	Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 12337-12342.	3.3	84
150	Oncogenic Activation of Pak1-Dependent Pathway of Macropinocytosis Determines BCG Entry into Bladder Cancer Cells. Cancer Research, 2013, 73, 1156-1167.	0.4	83
151	Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Cancer Discovery, 2020, 10, 198-213.	7.7	83
152	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. Journal of Clinical Oncology, 2021, 39, 2698-2709.	0.8	83
153	Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases. Oncotarget, 2017, 8, 66117-66127.	0.8	80
154	Clinical and molecular characterization of patients with cancer of unknown primary in the modern era. Annals of Oncology, 2017, 28, 3015-3021.	0.6	79
155	Clinical cancer genomic profiling. Nature Reviews Genetics, 2021, 22, 483-501.	7.7	79
156	Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Cancer Cell, 2021, 39, 1375-1387.e6.	7.7	78
157	Association with HSP90 Inhibits Cbl-Mediated Down-regulation of Mutant Epidermal Growth Factor Receptors. Cancer Research, 2006, 66, 6990-6997.	0.4	76
158	Somatic mutation of fibroblast growth factor receptorâ€3 (FGFR3) defines a distinct morphological subtype of highâ€grade urothelial carcinoma. Journal of Pathology, 2011, 224, 270-279.	2.1	73
159	Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies. Cancer Discovery, 2014, 4, 538-545.	7.7	73
160	Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. Cancer Cell, 2018, 34, 852-862.e4.	7.7	73
161	Clinical and Molecular Predictors of Response to Immune Checkpoint Inhibitors in Patients with Advanced Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 6160-6169.	3.2	73
162	Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma. Hepatology, 2021, 74, 1429-1444.	3.6	73

#	Article	IF	Citations
163	Therapeutic strategies for inhibiting oncogenic BRAF signaling. Current Opinion in Pharmacology, 2008, 8, 419-426.	1.7	72
164	Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. European Urology, 2020, 78, 671-679.	0.9	72
165	Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition. European Urology, 2016, 70, 771-775.	0.9	69
166	Pilot study of 68Ga-DOTA-F(abâ€²)2-trastuzumab in patients with breast cancer. Nuclear Medicine Communications, 2013, 34, 1157-1165.	0.5	68
167	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature Communications, 2021, 12, 3770.	5.8	68
168	Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer. Clinical Colorectal Cancer, 2012, 11, 101-111.	1.0	67
169	Transcriptional Mechanisms of Resistance to Antiâ€“PD-1 Therapy. Clinical Cancer Research, 2017, 23, 3168-3180.	3.2	67
170	3â€²-Deoxy-3â€²-[18F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK Inhibition. Cancer Research, 2007, 67, 11463-11469.	0.4	66
171	Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care. JAMA Oncology, 2020, 6, 84.	3.4	66
172	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. Journal of the National Cancer Institute, 2021, 113, 1683-1692.	3.0	66
173	Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell, 2021, 39, 793-809.e8.	7.7	65
174	A polyvalent vaccine for high-risk prostate patients: â€œare more antigens better?â€• Cancer Immunology, Immunotherapy, 2007, 56, 1921-1930.	2.0	64
175	Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis. Nature Communications, 2021, 12, 338.	5.8	64
176	Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nature Communications, 2022, 13, .	5.8	63
177	Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 1077-1085.	3.2	62
178	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. Journal of Clinical Oncology, 2020, 38, 406-414.	0.8	60
179	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Research, 2020, 22, 120.	2.2	60
180	A phase 2 study of the insulinâ€like growth factorâ€1 receptor inhibitor MKâ€0646 in patients with metastatic, wellâ€differentiated neuroendocrine tumors. Cancer, 2012, 118, 4795-4800.	2.0	59

#	Article	IF	Citations
181	PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology. American Journal of Surgical Pathology, 2019, 43, 920-927.	2.1	59
182	Genomic Landscape of Uterine Sarcomas Defined Through Prospective Clinical Sequencing. Clinical Cancer Research, 2020, 26, 3881-3888.	3.2	59
183	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. Cancer Research, 2017, 77, 6513-6523.	0.4	58
184	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. Oncologist, 2015, 20, 789-797.	1.9	57
185	Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation. New England Journal of Medicine, 2018, 378, 1945-1947.	13.9	56
186	Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2009, 27, 264-270.	0.8	55
187	JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors. Science Signaling, 2016, 9, ra33.	1.6	54
188	Mutant N-RAS Protects Colorectal Cancer Cells from Stress-Induced Apoptosis and Contributes to Cancer Development and Progression. Cancer Discovery, 2013, 3, 294-307.	7.7	53
189	Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Science Signaling, 2018, 11, .	1.6	53
190	A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2007, 59, 467-475.	1.1	52
191	How melanomas bypass new therapy. Nature, 2010, 468, 902-903.	13.7	52
192	A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma. JAMA Surgery, 2021, 156, e205601.	2.2	52
193	Frequency and outcomes of brain metastases in patients with HER2â€mutant lung cancers. Cancer, 2019, 125, 4380-4387.	2.0	51
194	OncoTree: A Cancer Classification System for Precision Oncology. JCO Clinical Cancer Informatics, 2021, 5, 221-230.	1.0	51
195	Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids. Cancer Research, 2003, 63, 8393-9.	0.4	51
196	Genomic characterization of response to chemoradiation in urothelial bladder cancer. Cancer, 2016, 122, 3715-3723.	2.0	50
197	Combination of RAF and MEK Inhibition for the Treatment of BRAF-Mutated Melanoma: Feedback Is Not Encouraged. Cancer Cell, 2014, 26, 603-604.	7.7	49
198	Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center. Pediatric Blood and Cancer, 2016, 63, 1368-1374.	0.8	49

#	Article	IF	Citations
199	ERK Pathway Inhibitors: How Low Should We Go?. Cancer Discovery, 2013, 3, 719-721.	7.7	47
200	HER2â€‰+â€‰breast cancers evade anti-HER2 therapy via a switch in driver pathway. Nature Communications, 2021, 12, 6667.	5.8	47
201	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF. Molecular Cancer Research, 2016, 14, 296-301.	1.5	46
202	A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. Breast Cancer Research, 2017, 19, 89.	2.2	45
203	Accelerating precision medicine in metastatic prostate cancer. Nature Cancer, 2020, 1, 1041-1053.	5.7	45
204	Realizing the Potential of Plasma Genotyping in an Age of Genotype-Directed Therapies. Journal of the National Cancer Institute, 2014, 106, dju214-dju214.	3.0	44
205	Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma. Clinical Cancer Research, 2019, 25, 674-686.	3.2	44
206	The context-specific role of germline pathogenicity in tumorigenesis. Nature Genetics, 2021, 53, 1577-1585.	9.4	44
207	Anatomic position determines oncogenic specificity in melanoma. Nature, 2022, 604, 354-361.	13.7	44
208	Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial. Gynecologic Oncology, 2020, 159, 150-156.	0.6	43
209	TNFR2/14-3-3Îµ signaling complex instructs macrophage plasticity in inflammation and autoimmunity. Journal of Clinical Investigation, 2021, 131, .	3.9	42
210	Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. PLoS ONE, 2015, 10, e0126633.	1.1	41
211	Therapeutic Strategies for Targeting BRAF in Human Cancer. Reviews on Recent Clinical Trials, 2007, 2, 121-134.	0.4	40
212	Towards a Unified Model of RAF Inhibitor Resistance. Cancer Discovery, 2014, 4, 27-30.	7.7	39
213	Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases. Cancer, 2017, 123, 568-575.	2.0	39
214	A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers.. Journal of Clinical Oncology, 2018, 36, 2502-2502.	0.8	39
215	Ganetespib, a Novel Hsp90 Inhibitor in Patients With KRAS Mutated and Wild Type, Refractory Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 2014, 13, 207-212.	1.0	37
216	Genomic landscape of inverted urothelial papilloma and urothelial papilloma of the bladder. Journal of Pathology, 2019, 248, 260-265.	2.1	37

#	Article	IF	Citations
217	Modeling biological and genetic diversity in upper tract urothelial carcinoma with patient derived xenografts. Nature Communications, 2020, 11, 1975.	5.8	37
218	Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition. Clinical Cancer Research, 2011, 17, 122-133.	3.2	36
219	Genomic Biomarkers for the Prediction of Stage and Prognosis of Upper Tract Urothelial Carcinoma. Journal of Urology, 2016, 195, 1684-1689.	0.2	36
220	Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma. Cancer, 2003, 98, 1842-1848.	2.0	35
221	MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions. Clinical Cancer Research, 2020, 26, 2932-2945.	3.2	35
222	Fragment Size Analysis May Distinguish Clonal Hematopoiesis from Tumor-Derived Mutations in Cell-Free DNA. Clinical Chemistry, 2020, 66, 616-618.	1.5	35
223	Clinical tumour sequencing for precision oncology: time for a universal strategy. Nature Reviews Cancer, 2018, 18, 527-528.	12.8	34
224	Regional differences in gallbladder cancer pathogenesis: Insights from a multiâ€institutional comparison of tumor mutations. Cancer, 2019, 125, 575-585.	2.0	34
225	The â€œSWOTâ€•of BRAF Inhibition in Melanoma: RAF Inhibitors, MEK Inhibitors or Both?. Current Oncology Reports, 2011, 13, 479-487.	1.8	33
226	The familial Parkinson Disease gene PARK2 is a multisite tumor suppressor on chromosome 6q25.2-27 that regulates cyclin E. Cell Cycle, 2010, 9, 1451-1452.	1.3	32
227	Oncologist use and perception of large panel next-generation tumor sequencing. Annals of Oncology, 2017, 28, 2298-2304.	0.6	31
228	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. Npj Breast Cancer, 2019, 5, 31.	2.3	31
229	Protein-altering germline mutations implicate novel genes related to lung cancer development. Nature Communications, 2020, 11, 2220.	5.8	31
230	PI3K pathway mutations are associated with longer time to local progression after radioembolization of colorectal liver metastases. Oncotarget, 2017, 8, 23529-23538.	0.8	31
231	A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 69, 1089-1097.	1.1	30
232	Summary and Recommendations from the National Cancer Instituteâ€™s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer, 2016, 2, 165-202.	0.2	30
233	Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma. Clinical Cancer Research, 2019, 25, 7475-7484.	3.2	30
234	Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. European Urology Focus, 2019, 5, 201-204.	1.6	30

#	Article	IF	Citations
235	Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation. American Journal of Surgical Pathology, 2021, 45, 77-92.	2.1	30
236	Genomic Characterization of Upper-Tract Urothelial Carcinoma in Patients With Lynch Syndrome. JCO Precision Oncology, 2018, 2018, 1-13.	1.5	29
237	Germ cell tumors and associated hematologic malignancies evolve from a common shared precursor. Journal of Clinical Investigation, 2020, 130, 6668-6676.	3.9	28
238	Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response.. Journal of Clinical Oncology, 2017, 35, 4511-4511.	0.8	28
239	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. Clinical Cancer Research, 2022, 28, 318-326.	3.2	28
240	Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Human Pathology, 2018, 77, 63-69.	1.1	27
241	Nextâ€generation sequencing of urine specimens: A novel platform for genomic analysis in patients with nonâ€“muscleâ€invasive urothelial carcinoma treated with bacille Calmetteâ€GuÃ©rin. Cancer Cytopathology, 2017, 125, 416-426.	1.4	26
242	Harnessing Clinical Sequencing Data for Survival Stratification of Patients With Metastatic Lung Adenocarcinomas. JCO Precision Oncology, 2019, 3, 1-9.	1.5	26
243	Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings. Cancer, 2020, 126, 1995-2002.	2.0	26
244	Lessons from the Study of Exceptional Responders. Cancer Cell, 2021, 39, 11-13.	7.7	26
245	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Medicine, 2021, 13, 96.	3.6	26
246	Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-GuÃ©rin Immunotherapy in Nonâ€“Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2021, 27, 4599-4609.	3.2	26
247	Rates of ERBB2 Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in an ERBB2-Amplified Acral Melanoma. Clinical Cancer Research, 2018, 24, 5815-5819.	3.2	25
248	Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas. Clinical Cancer Research, 2021, 27, 2226-2235.	3.2	25
249	Overcoming Adaptive Resistance to KRAS Inhibitors Through Vertical Pathway Targeting. Clinical Cancer Research, 2020, 26, 1538-1540.	3.2	25
250	Genomic Characterization of ERBB2-Driven Biliary Cancer and a Case of Response to Ado-Trastuzumab Emtansine. JCO Precision Oncology, 2019, 3, 1-9.	1.5	23
251	Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. European Urology, 2020, 78, 907-915.	0.9	21
252	Genomic Profile of Urothelial Carcinoma of the Upper Tract from Ureteroscopic Biopsy: Feasibility and Validation Using Matched Radical Nephroureterectomy Specimens. European Urology Focus, 2019, 5, 365-368.	1.6	20

#	Article	IF	Citations
253	Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Nonâ€“Small Cell Lung or Colorectal Cancer. JAMA Network Open, 2021, 4, e2117547.	2.8	20
254	Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric Cancer. Annals of Surgical Oncology, 2018, 25, 2027-2033.	0.7	19
255	Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. Clinical Cancer Research, 2021, 27, 2011-2022.	3.2	19
256	Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer. Cancer Research, 2020, 80, 4233-4243.	0.4	18
257	Tracing cancer networks with phosphoproteomics. Nature Biotechnology, 2010, 28, 1028-1029.	9.4	16
258	Mutational Analysis of Clonal Hematopoiesis in Solid Tumor Patients Illustrates the Critical Role of Systemic Anti-Cancer Therapies in the Evolution of Somatic Leukemia Disease Alleles. Blood, 2016, 128, 37-37.	0.6	16
259	Will Hsp90 Inhibitors Prove Effective in BRAF-Mutant Melanomas?. Clinical Cancer Research, 2012, 18, 2420-2422.	3.2	15
260	ARF Confers a Context-Dependent Response to Chemotherapy in Muscle-Invasive Bladder Cancer. Cancer Research, 2017, 77, 1035-1046.	0.4	15
261	Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. Clinical Cancer Research, 2021, 27, 1997-2010.	3.2	15
262	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. JAMA Network Open, 2021, 4, e2114753.	2.8	15
263	Molecular and phenotypic profiling of colorectal cancer patients in West Africa reveals biological insights. Nature Communications, 2021, 12, 6821.	5.8	15
264	Evaluation of Plasma Insulin-like Growth Factor Binding Protein 2 and Her-2 Extracellular Domain as Biomarkers for 17-Allylamino-17-Demethoxygeldanamycin Treatment of Adult Patients with Advanced Solid Tumors. Clinical Cancer Research, 2007, 13, 2121-2127.	3.2	14
265	Tumor Genetic Screening Programs: A Call to Action. Journal of Clinical Oncology, 2015, 33, 2725-2726.	0.8	14
266	Gene Signature Associated with Upregulation of the Wnt/Î²-Catenin Signaling Pathway Predicts Tumor Response to Transarterial Embolization. Journal of Vascular and Interventional Radiology, 2017, 28, 349-355.e1.	0.2	14
267	A phase 2 trial of buparlisib in patients with platinumâ€resistant metastatic urothelial carcinoma. Cancer, 2020, 126, 4532-4544.	2.0	14
268	Natural history, response to systemic therapy, and genomic landscape of plasmacytoid urothelial carcinoma. British Journal of Cancer, 2021, 124, 1214-1221.	2.9	14
269	Microsatellite instability in prostate cancer and response to immune checkpoint blockade.. Journal of Clinical Oncology, 2018, 36, 5020-5020.	0.8	14
270	Title is missing!. Angewandte Chemie, 2003, 115, 1318-1322.	1.6	13

#	Article	IF	Citations
271	Primed for resistance. Nature, 2012, 483, 44-45.	13.7	13
272	Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. Clinical Cancer Research, 2019, 25, 7381-7387.	3.2	13
273	Monitoring the Induction of Heat Shock Factor 1/Heat Shock Protein 70 Expression following 17-Allylamino-Demethoxygeldanamycin Treatment by Positron Emission Tomography and Optical Reporter Gene Imaging. Molecular Imaging, 2012, 11, 7290.2011.00028.	0.7	11
274	Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. Gastric Cancer, 2019, 22, 355-362.	2.7	11
275	Precision Oncology: Three Small Steps Forward. Cancer Cell, 2019, 35, 825-826.	7.7	11
276	Targeting HER2 mutationâ€“positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial.. Journal of Clinical Oncology, 2022, 40, 4079-4079.	0.8	11
277	RAF/MEK Dependence of KRAS-Mutant Pancreatic Ductal Adenocarcinomas: Figure 1.. Cancer Discovery, 2012, 2, 666-669.	7.7	10
278	Efficacy of Combined VEGFR1-3, PDGFÎ±/Î², and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer. Clinical Cancer Research, 2019, 25, 3811-3817.	3.2	10
279	Regorafenib in Combination with Firstâ€Line Chemotherapy for Metastatic Esophagogastric Cancer. Oncologist, 2020, 25, e68-e74.	1.9	10
280	Prevalence and Characterization of Biallelic and Monoallelic NTHL1 and MSH3 Variant Carriers From a Pan-Cancer Patient Population. JCO Precision Oncology, 2021, 5, 455-465.	1.5	10
281	AKT1 E17K Inhibits Cancer Cell Migration by Abrogating Î²-Catenin Signaling. Molecular Cancer Research, 2021, 19, 573-584.	1.5	10
282	Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms. Blood, 2018, 132, 49-49.	0.6	10
283	Local recurrences at the anastomotic area are clonally related to the primary tumor in sporadic colorectal carcinoma. Oncotarget, 2017, 8, 42487-42494.	0.8	10
284	AKT mutant allele-specific activation dictates pharmacologic sensitivities. Nature Communications, 2022, 13, 2111.	5.8	10
285	Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung Cancer. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1450-1459.	1.1	10
286	Oncogenic RAF: a brief history of time. Pigment Cell and Melanoma Research, 2010, 23, 760-762.	1.5	9
287	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. JCO Precision Oncology, 2020, 4, 1307-1320.	1.5	9
288	Generation of DOTA-Conjugated Antibody Fragments for Radioimmunoimaging. Methods in Enzymology, 2004, 386, 262-275.	0.4	8

#	Article	IF	Citations
289	Addressing the dichotomy between individual and societal approaches to personalised medicine in oncology. European Journal of Cancer, 2019, 114, 128-136.	1.3	8
290	Inverted urothelial papilloma and urothelial carcinoma with inverted growth are histologically and molecularly distinct entities. Journal of Pathology, 2020, 250, 464-465.	2.1	8
291	Association of RAS Mutation Location and Oncologic Outcomes After Resection of Colorectal Liver Metastases. Annals of Surgical Oncology, 2021, 28, 817-825.	0.7	8
292	Next-Generation Sequencing of 487 Esophageal Adenocarcinomas Reveals Independently Prognostic Genomic Driver Alterations and Pathways. Clinical Cancer Research, 2021, 27, 3491-3498.	3.2	8
293	Novel Mouse Models of Bladder Cancer Identify a Prognostic Signature Associated with Risk of Disease Progression. Cancer Research, 2021, 81, 5161-5175.	0.4	7
294	DNA damage response (DDR) gene mutations (mut), mut load, and sensitivity to chemotherapy plus immune checkpoint blockade in urothelial cancer (UC).. Journal of Clinical Oncology, 2017, 35, 300-300.	0.8	7
295	Monitoring the induction of heat shock factor 1/heat shock protein 70 expression following 17-allylamino-demethoxygeldanamycin treatment by positron emission tomography and optical reporter gene imaging. Molecular Imaging, 2012, 11, 67-76.	0.7	7
296	Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 362-371.	1.1	7
297	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. Cancer Discovery, 2022, 12, 2308-2329.	7.7	7
298	Opportunities and Challenges in Genomic Sequencing for Precision Cancer Care. Annals of Internal Medicine, 2018, 168, 221.	2.0	6
299	Real-World Outcomes of an Automated Physician Support System for Genome-Driven Oncology. JCO Precision Oncology, 2019, 3, 1-13.	1.5	6
300	The Genetic Evolution of Treatment-Resistant Cutaneous, Acral, and Uveal Melanomas. Clinical Cancer Research, 2021, 27, 1516-1525.	3.2	6
301	Prognostic significance of DNA damage repair (DDR) mutations in patients with urothelial carcinoma (UC) and associations with tumor infiltrating lymphocytes (TILs).. Journal of Clinical Oncology, 2016, 34, 4538-4538.	0.8	6
302	The Role of the TP53 Pathway in Predicting Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma. Clinical Cancer Research, 2022, 28, 2669-2678.	3.2	6
303	Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer.. Journal of Clinical Oncology, 2022, 40, 1010-1010.	0.8	6
304	Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype. JCO Precision Oncology, 2022, , .	1.5	6
305	Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 70, 201-205.	1.1	5
306	Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver. Cancer, 2020, 126, 4126-4135.	2.0	5

#	Article	IF	Citations
307	RAS/MAPK Pathway Driver Alterations Are Significantly Associated With Oncogenic KIT Mutations in Germ-cell Tumors. Urology, 2020, 144, 111-116.	0.5	5
308	Identifying treatment options for BRAFV600 wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial. PLoS ONE, 2021, 16, e0248097.	1.1	5
309	Defining and Targeting Esophagogastric Cancer Genomic Subsets With Patient-Derived Xenografts. JCO Precision Oncology, 2022, 6, e2100242.	1.5	5
310	Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy. Clinical Genitourinary Cancer, 2022, 20, 431-441.	0.9	5
311	Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma. Clinical Genitourinary Cancer, 2016, 14, e81-e90.	0.9	4
312	Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Nonâ€“Muscle-Invasive Bladder Cancer. Clinical Cancer Research, 2022, 28, 4267-4277.	3.2	4
313	Annotation of Somatic Genomic Variants in Hematologic Diseases Using OncoKB, a Precision Oncology Knowledgebase. Blood, 2019, 134, 2148-2148.	0.6	3
314	BRAF Mutations: The Discovery of Allele- and Lineage-Specific Differences. Cancer Research, 2022, 82, 12-14.	0.4	3
315	HER-Kinase-Directed Therapy of Prostate Cancer. Prostate Journal, 2001, 3, 53-58.	0.2	2
316	CD274 (PD-L1) Copy Number Changes (Gain) & Response to Immune Checkpoint Blockade Therapy in Carcinomas of the Urinary Tract. Bladder Cancer, 2021, 7, 1-6.	0.2	2
317	Utility of Serial cfDNA NGS for Prospective Genomic Analysis of Patients on a Phase I Basket Study. JCO Precision Oncology, 2021, 5, 6-16.	1.5	2
318	Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. , 0, .		2
319	Frequency of actionable cancer predisposing germline mutations in patients with lung cancers.. Journal of Clinical Oncology, 2018, 36, 1504-1504.	0.8	2
320	Reply to M.P. Decatris et al. Journal of Clinical Oncology, 2016, 34, 887-887.	0.8	1
321	Commentary on â€œDNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma.â€• Urologic Oncology: Seminars and Original Investigations, 2018, 36, 345-346.	0.8	1
322	â€œPrimaryâ€•and â€œsecondaryâ€•muscle-invasive bladder cancer is more than just a surrogate for molecular subtypes. Translational Cancer Research, 2019, 8, S642-S644.	0.4	1
323	Aggressive Hematopoietic Malignancy Characterized by Biallelic Loss of SMARCB1. JCO Precision Oncology, 2020, 4, 1280-1284.	1.5	1
324	HGF/MET rescues Gefitinib treated non-small cell lung cancer cells carrying an activating EGFR mutation. Journal of the American College of Surgeons, 2008, 207, S100-S101.	0.2	0

#	Article	IF	Citations
325	BRAF mutations in human cancer: biologic and therapeutic implications. , 0, , 272-277.		0
326	Intracellular Signaling. , 2020, , 24-46.e12.		0
327	37. Spatiotemporal patterns of metastatic spread and survival from MSK-IMPACT, a large-scale prospective clinical sequencing. Cancer Genetics, 2020, 244, 14.	0.2	0
328	Re: Russell E.N. Becker, Alexa R. Meyer, Aaron Brant, et al. Clinical Restaging and Tumor Sequencing are Inaccurate Indicators of Response to Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.016. European Urology, 2021, 79, e56-e57.	0.9	0
329	CHEMOTHERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER. , 2011, , 559-615.		0
330	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Blood, 2015, 126, 481-481.	0.6	0
331	Next-Generation Sequencing of Matched Normal Blood Identifies Clonal Hematopoiesis in a Significant Subset of Solid Tumor Patients without Hematologic Malignancies. Blood, 2015, 126, 2447-2447.	0.6	0
332	Interplay between Chromosomal Alterations and Gene Mutations Shapes the Evolutionary Trajectory of Clonal Hematopoiesis. Blood, 2020, 136, 29-30.	0.6	0
333	Overcoming barriers to tumor genomic profiling through direct patient social media outreach.. Journal of Clinical Oncology, 2022, 40, 6532-6532.	0.8	0
334	Immunogenomic characterization of biliary tract cancers: Biomarker enrichment for benefit to immune checkpoint blockade.. Journal of Clinical Oncology, 2022, 40, 4083-4083.	0.8	0
335	Next-generation sequencing (NGS) of circulating cell-free DNA (cfDNA) in patients (pts) with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2022, 40, 4110-4110.	0.8	0